SCHEMBL6323221

SCHEMBL6323221

COc1ccc(S(=O)(=O)N(C)[C@H](C)CS)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.61
POLB P06746 1/20 0.61
KMT2A Q03164 1/20 0.61
MMP13 P45452 8/20 0.55
MMP1 P03956 5/20 0.55
PGR P06401 1/20 0.48
KEAP1 Q14145 4/20 0.47
MMP8 P22894 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PKM P14618 1/20 0.46
MMP2 P08253 1/20 0.45
MMP3 P08254 1/20 0.45
MMP9 P14780 1/20 0.45
MMP14 P50281 1/20 0.45
NFE2L2 Q16236 2/20 0.45
BMP1 P13497 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323218 1.00 MEN1 (0.61) MEN1POLBKMT2AMMP13MMP1
SCHEMBL6320953 0.85 LMNA (0.62) MEN1POLBKMT2AMMP13MMP1
SCHEMBL6324860 0.85 CA12 (0.49) MEN1POLBKMT2AMMP13MMP1
SCHEMBL6324864 0.85 CA12 (0.49) MEN1POLBKMT2AMMP13MMP1
SCHEMBL6320950 0.85 LMNA (0.62) MEN1POLBKMT2AMMP13MMP1
SCHEMBL6325694 0.84 MEN1 (0.57) MEN1POLBKMT2AMMP13MMP1
SCHEMBL6325691 0.84 MEN1 (0.57) MEN1POLBKMT2AMMP13MMP1
SCHEMBL6325747 0.82 CA12 (0.51) MEN1POLBKMT2AMMP13MMP1
SCHEMBL6325750 0.82 CA12 (0.51) MEN1POLBKMT2AMMP13MMP1
SCHEMBL6324332 0.81 MMP13 (0.51) MEN1POLBKMT2AMMP13MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 MEN1 2943/4885POLB 2981/4885KMT2A 1531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.